Archive | Clinical Trials

Nivolumab Shows Benefit After Progression in Advanced Melanoma

Treatment of advanced melanoma with the checkpoint inhibitor nivolumab beyond RECIST-defined progression resulted in clinical benefit for selected patients, according to pooled, retrospective data from two phase III trials.

Read the full story

Posted in Melanoma In The News, Clinical Trials

AMA grants procedure codes for pigmented lesion assay for melanoma

DermTech has reported that the AMA has granted the company category 1, tier 2 molecular pathology procedure codes related to its proprietary test for the detection of melanoma-related gene expression.

Read the full story

Posted in Melanoma In The News, Clinical Trials

CheckMate 037: Nivolumab Improved Responses, Not Survival in Advanced Melanoma

Patients with advanced melanoma treated with nivolumab had higher and more durable responses compared with investigator’s choice of chemotherapy, but these increases did not result in improved survival outcomes, according to the results of the CheckMate 037 study published in the Journal of Clinical Oncology.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Pembrolizumab Plus Reduced-dose Ipilimumab Safe in Advanced Melanoma

Patients with advanced melanoma may have good outcomes when treated with standard-dose pembrolizumab with 4 doses of reduced-dose ipilimumab, according to a study published in The Lancet Oncology.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories